ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., JUNE 19, 2003 Amgen...(NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth...Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a second phase 3 clinical study assessing the efficacy and tolerability of ENBREL (etanercept) in the treatment of moderate to severe plaque psoriasis experienced significant a...ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and...Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients receiving ENBREL(R) (etanercept) 50 mg once weekly for the treatment of active rheumatoid arthritis (RA) in a new clinical study experienced significant improvements in function and pain that were comparable to those receivin...ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 20, 2003 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced results of a new study assessing the efficacy of combination treatment with ENBREL (etanercept) and methotrexate in rheumatoid arthritis (RA) patients, compared with ENBREL or methotrexate alone. One-year results of TEMPO, (Trial of Etanerc...ENBREL is first therapy approved for psoriatic arthritis
SEATTLE, WA Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has approved ENBREL (etanercept) to treat people with psoriatic arthritis. ENBREL is the first therapy to receive approval to reduce the signs and symptoms of active arthritis in patients with psoriatic ar...New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
SAN FRANCISCO, November 11, 2001 Data from a Phase 2 clinical study of ENBREL (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American College of Rheumatology. This study, conducted by Dr. John Davis and colleagues at the University of California, San Francisco, is the first randomized, placebo-controlled study of ENBREL for the tre...Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
... ...SAN FRANCISCO, November 11, 2001 Phase 3 results of ENBREL (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology National Scientific Meeting in San Francisco.... ...Psoriatic arthritis is a devastating disease for which there are currently no approved treatments, says Philip Mease, MD, Seattle Rheumatol...... ...Positive Results of Phase I Study Presented ...At American College of Cardiology Conference ... ...SEATTLE -- Immunex Corporation (NASDAQ:IMNX and Wyeth-Ayerst Laboratories...announced today that they are beginning a Phase II/III clinical trial with...ENBREL (etanercept) in chronic heart failure patients, one of the first...large-scale studies undertaken to evaluate cy...